QGEN logo

QIAGEN N.V.

QGENNYSE
πŸ† #930 by market capEarnings Nov 3US Equity
$44.40β–Ό $0.60 (βˆ’1.36%)
πŸŒ™ After hours$44.40β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track QGEN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.4%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$9.16B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+5.7%
Slowing
πŸ“ŠGross Margin
61.8%
High
πŸ’΅FCF Margin
21.3%
Strong
βš–οΈP/S Ratio
4.4x
Fair
Otter Score
76
Good
No chart data available for QGEN.

Trading Snapshot

Day Range
$44.20 – $44.79
52-Week Range
$32.53 – $57.82
Volume
$3.28B
Avg Volume
$3.09B
Shares Outstanding
206.3M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$2.09B
Last Q Revenue
$535M
P/E Ratio
23.1
P/S Ratio
4.4x
EPS (TTM)
$1.98
Dividend Yield
5.87%
Dilution (1yr)
βˆ’4.7%

Why Investors Own QGEN

  • βœ“High-growth profile β€” revenue up +22.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 30% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

QGEN logo

QIAGEN N.V.

QGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.1Bβ–² +5.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.8%β–² +26.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$520Mβ–² +432.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$453Mβ–Ό βˆ’10.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
207.8Mβ–Ό βˆ’4.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$815Mβ–² +$130M YoY
StockOtter Β· stockotter.space

About QIAGEN N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$59.17
β–² +33.3% Upside
High Target$70.71
Low Target$45.27
Based on 14 analysts

Latest News & Updates

Business WireΒ·1d ago

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstre

Defense WorldΒ·3d ago

Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51

Qiagen N.V. (NYSE: QGEN - Get Free Report) has been given an average rating of "Hold" by the fourteen brokerages that are covering the company, Marketbeat reports. Nine analysts have rated the stock with a hold recommend

Business WireΒ·5d ago

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system design

Zacks Investment ResearchΒ·5d ago

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

GuruFocusΒ·8d ago

A Look at Qiagen NV (QGEN) After 3.4% Gain -- GF Value $49.88 vs Price $44.78

On September 21, 2026, Qiagen NV (QGEN) shares rose 3.4% to $44.78, demonstrating a notable increase amidst a challenging year, with a 52-week range of $32.53 t

Business WireΒ·11d ago

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Share